# Withdrawal Syndrome Following Opioid Rotation: Tramadol and Its Unique Pharmacology

**Authors:** Matthew A Murphy

PMC · DOI: 10.7759/cureus.102584 · Cureus · 2026-01-29

## TL;DR

A patient experienced withdrawal symptoms after switching from tramadol to oxycodone, highlighting tramadol's unique opioid effects.

## Contribution

This case emphasizes tramadol's distinct pharmacology and withdrawal profile compared to other opioids.

## Key findings

- Opioid rotation from tramadol to oxycodone triggered withdrawal-like symptoms.
- Increasing oxycodone dosage alleviated the patient's symptoms.
- Tramadol's unique properties may lead to different withdrawal patterns.

## Abstract

A 33-year-old woman with chronic myeloid leukemia and a history of generalized anxiety disorder and major depressive disorder presented to the hospital with severe anxiety. Two days earlier, she reported escalating cancer-related pain despite taking tramadol 100 mg orally three times per day. Following opioid rotation to oxycodone 5 mg orally every six hours as needed, her pain improved, but she developed anxiety and restlessness consistent with opioid withdrawal, prompting hospital evaluation. Her symptoms resolved following opioid dose escalation to oxycodone 10 mg orally every four hours as needed. This case highlights the potential for withdrawal during opioid rotation and underscores tramadol’s unique pharmacology, which may differentiate its withdrawal syndrome from that of other opioid analgesics.

## Linked entities

- **Chemicals:** tramadol (PubChem CID 19472), oxycodone (PubChem CID 5284603)
- **Diseases:** chronic myeloid leukemia (MONDO:0011996), generalized anxiety disorder (MONDO:0001942), major depressive disorder (MONDO:0002009)

## Full-text entities

- **Genes:** CYP2D6 (cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)) [NCBI Gene 1565] {aka CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2}
- **Diseases:** mood, neuropsychiatric, and sensory disturbances (MESH:D019964), suicidal ideation (MESH:D001072), respiratory depression (MESH:D012131), nausea (MESH:D009325), diarrhea (MESH:D003967), hypotension (MESH:D007022), noradrenergic hyperactivity (MESH:D006948), opioid (MESH:D009293), anxiety disorder (MESH:D001008), analgesia (MESH:D000699), vomiting (MESH:D014839), trauma (MESH:D014947), Pain (MESH:D010146), insomnia (MESH:D007319), substance use disorders (MESH:D019966), cancer (MESH:D009369), neuropsychiatric, and sensory disturbances (MESH:D012678), chronic myeloid leukemia (MESH:D015464), anxiety (MESH:D001007), autonomic hyperactivity (MESH:D000430), depressed (MESH:D003866), myalgias (MESH:D063806), opioid tolerance (MESH:D018149), hallucinations (MESH:D006212), Withdrawal Syndrome (MESH:D013375), major (MESH:D004830), restlessness (MESH:D011595), psychosis (MESH:D011618)
- **Chemicals:** buspirone (MESH:D002065), venlafaxine (MESH:D000069470), norepinephrine (MESH:D009638), clonidine (MESH:D003000), asciminib (MESH:C000621806), fluoxetine (MESH:D005473), morphine (MESH:D009020), T3 (MESH:D014284), Tramadol (MESH:D014147), alcohol (MESH:D000438), serotonin (MESH:D012701), hydromorphone (MESH:D004091), T4 (MESH:D013974), SNRI (-), mercury (MESH:D008628), oxycodone (MESH:D010098), O-desmethyltramadol (MESH:C080580), lorazepam (MESH:D008140)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949668/full.md

## References

20 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949668/full.md

---
Source: https://tomesphere.com/paper/PMC12949668